Simultaneous development of IgA vasculitis and eosinophilic granulomatosis with polyangiitis

References

• Audemard-Verger A, Pillebout E, Guillevin L, et al. IgA vasculitis (Henoch-Shonlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–585.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and management of IgA vasculitis (Henoch-Schonlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol. 2017;69(9):1862–1870.
   PubMed Web of Science ®Google Scholar
• Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–1202.
   PubMed Web of Science ®Google Scholar
• Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schonlein purpura in Taiwan. Rheumatology (Oxford). 2005;44(5):618–622.
   Web of Science ®Google Scholar
• Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19(2):191–207.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in Northwestern Spain, 1988–1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78(5):292–308.
   Web of Science ®Google Scholar
• Gioffredi A, Maritati F, Oliva E, et al. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 2014;5:549.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68(3):261–273.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, Shirai T, Berry G, et al. T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48–49:99–103.
   Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Oshikata C, et al. High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis. Clin Transl Allergy. 2014;4(1):38.
   Google Scholar
• Davin JC, Coppo R. Henoch-Schonlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563–573.
   PubMed Web of Science ®Google Scholar
• Novak J, Julian BA, Mestecky J, et al. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012;34(3):365–382.
   PubMed Web of Science ®Google Scholar
• Allen AC, Willis FR, Beattie TJ, et al. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998;13(4):930–934.
   Web of Science ®Google Scholar
• Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol. 2012;23(5):814–824.
   PubMed Web of Science ®Google Scholar
• Chintalacharuvu SR, Nagy NU, Sigmund N, et al. T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol. 2001;126(2):326–333.
   Web of Science ®Google Scholar
• Chintalacharuvu SR, Yamashita M, Bagheri N, et al. T cell cytokine polarity as a determinant of immunoglobulin A (IgA) glycosylation and the severity of experimental IgA nephropathy. Clin Exp Immunol. 2008;153(3):456–462.
   PubMed Web of Science ®Google Scholar
• Inoshita H, Kim BG, Yamashita M, et al. Disruption of Smad4 expression in T cells leads to IgA nephropathy-like manifestations. PLoS One. 2013;8(11):e78736.
   Web of Science ®Google Scholar
• Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25(12):3890–3897.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668–1677.
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414.
   PubMed Web of Science ®Google Scholar
• Smith AC, Molyneux K, Feehally J, et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006;17(12):3520–3528.
   PubMed Web of Science ®Google Scholar
• Davin JC, Forget P, Mahieu PR. Increased intestinal permeability to (51 Cr) EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies. Acta Paediatr Scand. 1988;77(1):118–124.
   Web of Science ®Google Scholar
• de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int. 1996;50(3):952–961.
   Web of Science ®Google Scholar
• Sada KE, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol. 2014;24(4):640–644.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol. 2012;24(1):24–30.
   Web of Science ®Google Scholar
• Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–163.
   PubMed Web of Science ®Google Scholar
• Koike H, Akiyama K, Saito T, et al. Research Group for IfECSSiJ. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol. 2015;262(3):752–759.
   PubMed Web of Science ®Google Scholar
• Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol. 1991;88(5):823–824.
   Web of Science ®Google Scholar
• Matsumoto T, Otsuka K, Kawamoto M, et al. Efficacy of early intravenous immunoglobulin for eosinophilic granulomatosis with polyangiitis with drastically progressive neuropathy: a synopsis of two cases. Intern Med. 2013;52(8):913–917.
   Web of Science ®Google Scholar
• Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–1017.
   PubMed Web of Science ®Google Scholar